Pulse Biosciences, Inc.PLSE

Pulse Biosciences Inc. (PLSE) started the third quarter with a quarterly revenue tally that would make a small retail counter blush: $401,000 in the three months to 31 March 2026, a figure so small that even the company’s own website greets it with the studied silence of a polite cough. Net loss for the same period came in at $18.6 million, turning every dollar of product revenue into a $46 loss before the coffee break. The operating loss of $19.1 million tells the real story, because at Pulse Biosciences the lights stay on mainly by keeping the lights dim: cash and equivalents stood at $68.3 million on 31 March, but the company burned $14.6 million of operating cash, a pace that would close the doors in less than five quarters if the bleeding does not slow. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1625101/000143774926020719/xslF345X06/rdgdoc.xml)

What Pulse actually sells is Nanosecond Pulsed Field Ablation™ technology, delivered through a generator platform called nPulse™ that promises to ablate soft tissue non-thermally while sparing nearby non-cellular structures. The marketing copy is sleek-“nanosecond pulses from billionths up to a millionth of a second,” “the first commercial product to harness the distinctive advantages of nsPFA”-but the filing reality is a single-digit revenue line, $401,000, that would buy fewer than 1,400 ablation cartridges at any remotely commercial price. The technology may be novel; the market adoption is not yet visible. (source: Technology, https://www.pulsebiosciences.com/technology/; 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1625101/000143774926020719/xslF345X06/rdgdoc.xml)

The balance sheet shows $81.6 million of assets versus $15.3 million of liabilities on 31 March 2026, leaving shareholders with $66.3 million of equity-numbers that look healthier than the operating story until you notice the $12.6 million quarterly R&D spend and the $33,000 spent on ‘property, plant and equipment,’ a line so thin it reads like a rounding error. Inventory crept up by $70,000 to $206,000, a figure that suggests unsold prototypes rather than a supply chain humming with orders. The June 10, 2026 press release cheerfully announced an “irrevocable notice of redemption” for outstanding warrants, a bureaucratic nicety that does little to mask the operating haemorrhage. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1625101/000143774926020719/xslF345X06/rdgdoc.xml; Press Release dated 2026-06-10, https://www.sec.gov/Archives/edgar/data/1625101/000143774926020085/ex_973581.htm)

Chart context is thin on this name: Pulse Biosciences trades on the OTCQB with thin liquidity, and the evidence pack does not supply a chart route. The stock’s real story is on the filing rail, not the price rail, where revenue of $401,000 and a quarterly burn of $14.6 million are the only facts that matter. Until the company ships real revenue or publishes a credible clinical revenue milestone, the chart remains a sideshow. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1625101)

What changed this week: Pulse Biosciences filed its Q1 2026 10-Q on the public record, confirming the revenue and cash-burn figures and updating the inventory line. The company also posted an 8-K on 12 June 2026 to announce the warrant redemption timeline, a procedural move that does not alter the operating fundamentals. What remains unproven: any recurring revenue above $401,000, any sustained gross margin, any regulatory approvals that convert into billable procedures, and any path to cash-flow breakeven inside the current cash runway. Concrete evidence that would deepen the file includes a quarterly revenue print above $1 million, publication of peer-reviewed clinical utilisation data with revenue codes, or a named commercial partnership or distribution agreement with a hospital group or device distributor. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1625101; 8-K dated 2026-06-12, https://www.sec.gov/Archives/edgar/data/1625101/000143774926020464/plse20260607c_8k.htm)